BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7493336)

  • 1. Experimental approaches to increase radiolabeled antibody localization in tumors.
    Buchsbaum DJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5729s-5732s. PubMed ID: 7493336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
    J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels.
    Shockley TR; Lin K; Sung C; Nagy JA; Tompkins RG; Dedrick RL; Dvorak HF; Yarmush ML
    Cancer Res; 1992 Jan; 52(2):357-66. PubMed ID: 1728407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological considerations for radioimmunotherapy.
    Sharkey RM; Blumenthal RD; Hansen HJ; Goldenberg DM
    Cancer Res; 1990 Feb; 50(3 Suppl):964s-969s. PubMed ID: 2297750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
    King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
    Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
    Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.
    Sung C; Shockley TR; Morrison PF; Dvorak HF; Yarmush ML; Dedrick RL
    Cancer Res; 1992 Jan; 52(2):377-84. PubMed ID: 1728409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo tumor models for studies of distribution of radiolabelled monoclonal antibodies and fragments.
    Buchegger F; Halpern SE; Sutherland RM; Schreyer M; Mach JP
    Nuklearmedizin; 1986 Dec; 25(6):207-9. PubMed ID: 3808959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
    Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
    Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting.
    Schlom J; Hand PH; Greiner JW; Colcher D; Shrivastav S; Carrasquillo JA; Reynolds JC; Larson SM; Raubitschek A
    Cancer Res; 1990 Feb; 50(3 Suppl):820s-827s. PubMed ID: 1688734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.
    Jain M; Venkatraman G; Batra SK
    Clin Cancer Res; 2007 Mar; 13(5):1374-82. PubMed ID: 17309914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.